Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670169 | 0.97 | CA12 (0.32) | CA12CA1CA9 | |
| SCHEMBL20591109 | 0.89 | — | — | |
| SCHEMBL20591110 | 0.87 | — | — | |
| SCHEMBL2545853 | 0.77 | RIPK1 (0.31) | — | |
| SCHEMBL16694227 | 0.77 | ACHE (0.43) | — | |
| SCHEMBL29590012 | 0.77 | ACHE (0.43) | — | |
| SCHEMBL29670084 | 0.75 | ACHE (0.41) | — | |
| SCHEMBL2550793 | 0.74 | ACHE (0.39) | CA1CA9 | |
| SCHEMBL2551368 | 0.73 | — | — | |
| SCHEMBL15603766 | 0.72 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213376-B2 | Organic photoelectric conversion material | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20220310939-A1 | ORGANIC PHOTOELECTRIC CONVERSION MATERIAL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-4024486-A1 | ORGANIC PHOTOELECTRIC CONVERSION MATERIAL | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-110741028-B | Method for producing polymer compound | 住友化学株式会社 | 2022-05-03 | — | — | CN | disclosed |
| CN-110003271-B | Process for producing aromatic compound | 住友化学株式会社 | 2022-05-03 | — | — | CN | disclosed |
| EP-2871198-B1 | METHOD FOR PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9453103-B2 | Method for producing aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150322199-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-2871198-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2015-05-13 | — | — | EP | disclosed |
| EP-2552928-B1 | A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST. | CHROMAFORA AB (SE) | 2015-04-15 | — | — | EP | disclosed |
| US-8426647-B2 | — | — | 2013-04-23 | — | — | US | disclosed |
| EP-2552928-A1 | A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | Chromafora AB (SE) | 2013-02-06 | — | — | EP | disclosed |
| US-20130012725-A1 | PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | CHROMAFORA AB (SE) | 2013-01-10 | — | — | US | disclosed |
| WO-2011123037-A1 | A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | CHROMAFORA AB (SE) | 2011-10-06 | — | — | WO | disclosed |
| US-7847126-B2 | prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example | LANXESS DEUTSCHLAND GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| EP-1354886-B1 | Process for the preparation of tertiary phosphines | SALTIGO GMBH (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20070299273-A1 | prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example | LANXESS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| US-7230136-B2 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20030229240-A1 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1354886-A1 | Process for the preparation of tertiary phosphines | Bayer Aktiengesellschaft (DE) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322199-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | PAH, DDC, DDT | CA12 889/4885CA1 1065/4885CA9 330/4885 |
| US-20130012725-A1 | PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | PSPH, PNPO, PHOSPHO1 | CA12 1870/4885CA1 1143/4885CA9 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.